Absorption , Metabolism , and Excretion of 14 C-Temozolomide following Oral Administration to Patients with Advanced Cancer 1

@inproceedings{Baker1999AbsorptionM,
  title={Absorption , Metabolism , and Excretion of 14 C-Temozolomide following Oral Administration to Patients with Advanced Cancer 1},
  author={Sharyn D. Baker and Mark A Wirth and Paul Statkevich and Pascale Reidenberg and Kevin B. Alton and Susan E. Sartorius and Margaret Dugan and David Cutler and Vijay Batra and Louise B. Grochow and Ross C. Donehower and Eric K. Rowinsky},
  year={1999}
}
The purpose of this study is to characterize the absorption, metabolism, and excretion of carbon 14-labeled temozolomide (C-TMZ) administered p.o. to adult patients with advanced solid malignancies. On day 1 of cycle 1, six patients received a single oral 200-mg dose ofC-TMZ (70.2 mCi). Whole blood, plasma, urine, and feces were collected from days 1–8 and on day 14 of cycle 1. Total radioactivity was measured in all samples. TMZ, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), and 4… CONTINUE READING